<img height="1" width="1" src="https://www.facebook.com/tr?id=1475348972529988&amp;ev=PageView &amp;noscript=1">
Home
About
Why Milton Park?
Getting Here
Availability
News & Events
Work Here
Downloads
Contact Us

Summit Therapeutics growth sees expansion at Milton Park

Published on: 23/05/2017

Summit Therapeutics has recently taken a new unit at Milton Park.

The drug discovery and development company, which initially moved to the park in 2005, has taken a 6,780 sq ft unit at 136a Eastern Avenue. This is the third time that Summit Therapeutics has moved at Milton Park, demonstrating the company’s continued growth and evolution over the past 10 years as it advances its pipeline of investigational new medicines.

The new site will enable the approximate 45-strong company to recruit further to continue its focus on developing a treatment for Duchenne muscular dystrophy (DMD), a rare and fatal genetic disease, and advancing a new antibiotic for the treatment of infections caused by the bacteria Clostridium difficile.

As part of its global growth strategy, Summit Therapeutics opened offices in Cambridge Massachusetts, USA in 2014, which supports them in carrying out global clinical trials and providing access to an important international market.

The news comes as the company recently announced that it will proceed with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial for its utrophin modulation programme, which is a potential disease-modifying approach to treat all patients with DMD. It also recently reported positive Phase 2 data on its C. difficile antibiotic with these results published in The Lancet Infectious Diseases in April 2017.

James Dipple, CEO, MEPC said: “Summit Therapeutics is an extremely dedicated group of researchers and its work is a vital contribution to our scientific community. We are very pleased to be part of the company’s growth and to be giving them the opportunity to continue their ground-breaking research. Their expansion is testament to the nurturing environment we have worked hard to create at Milton Park. We look forward to seeing them thrive in years to come.”

Glyn Edwards, Chief Executive Officer, Summit Therapeutics added: “Milton Park’s location within the UK biotechnology community provides the ideal environment for Summit to undertake its development of innovative treatments for Duchenne muscular dystrophy and C. difficile infection. We are pleased to have found new premises that will support our continued growth as we advance our programmes through clinical trials and towards patients and their families.”

  All news stories

Got some news to share?

Tell us about your achievements and what you have been up to.
Submit a story

Submit News

Submission Terms and Conditions

Terms and conditions for submitting an event, news story or directory item onto Milton Park’s website: www.miltonpark.co.uk

  1. miltonpark.co.uk is owned and run by MEPC Ltd, owners and managers of Milton Park, Oxfordshire
  2. All submissions are forwarded to the Marketing Executive for approval before upload
  3. Content submitted may be subject to change
  4. Content must be written in good English and grammatically correct
  5. If the submission is not deemed suitable or relevant it will not be uploaded
  6. Content must be clear, easy to read, understandable and relevant to the occupiers of Milton Park
  7. Once uploaded, items are subject to deletion at any time
  8. Upon submission, you will receive a confirmation email with a copy of these terms and conditions for reference
  9. Upon submission, items will be uploaded within 3 working days if suitable
  10. Classifieds are deleted after six months of upload
  11. News stories are archived monthly and remain on the Website for one year
  12. Events are archived monthly and remain on the Website for one year
  13. Companies listed on the website will be removed when leaving Milton Park